ACTO Celebrates Recognition as a Luminary in Everest Group's Innovative AI in Life Sciences Assessment 2026

In a significant achievement, ACTO has been named a Luminary in the Everest Group's latest report titled "Innovation Watch: Agentic AI in Life Sciences Commercial 2026." This recognition highlights ACTO's pioneering role in merging human intelligence with empathetic artificial intelligence (AI) tailored specifically for the Life Sciences sector.

The Everest Group's assessment evaluates top players in the agentic AI technology field, focusing on their performance, market presence, and ecosystem drivers. Out of the 22 contenders, ACTO's innovative solutions positioned it in the top-tier Luminary category, which reflects not only its strong market performance but also its collaborative ecosystem with vital partnerships and investments.

Rohit K, the Practice Director at Everest Group, emphasized the importance of agentic AI as a transformational force within Life Sciences. The report identifies diverse opportunities for organizations, covering areas like sales, marketing, medical affairs, market access, and patient services. By leveraging agentic AI, companies can enhance decision-making, automate operations, and foster personalized engagements across various sectors.

"As companies embrace agentic AI across their commercial functions, they are looking beyond standalone applications to integrated platforms that efficiently link data, content, and workflows across different roles and systems," said Rohit K.

ACTO sets itself apart through its role-based SuperAgents, which utilize domain-specific expertise and cross-platform orchestration. This method not only adheres to the stringent regulatory standards in the industry but ensures a responsive and compliant approach to supporting healthcare professionals, thereby enhancing user engagement.

The company began its investment in AI technology back in 2022, with the introduction of LAICA, an AI-powered conversational assistant designed for Life Sciences training. This initiative paved the way for the development of ACTO SuperAgents, which were officially launched in 2026.

Co-founder and CEO of ACTO, Parth Khanna, expressed excitement over this recognition, stating, "Being named a Luminary by the Everest Group alongside our strategic partners such as Veeva and Salesforce is a tremendous honor. Our mission has always been to harness AI's potential not to replace humans but to augment their capabilities." Khanna emphasized the real-world impact their SuperAgents are delivering by understanding the user’s role, the context of their work, and the regulatory environment unique to Life Sciences.

ACTO's innovative platform is designed to optimize the work of customer-facing professionals, ensuring they spend less time managing systems and more time engaging with healthcare providers. The result is not just efficiency but the cultivation of meaningful relationships essential in the healthcare landscape.

This recent accolade follows ACTO's inclusion earlier this year among Everest Group's Top 50™ Pharmaceutical Technology Providers for 2026, further underscoring the company's commitment to enhancing AI-powered field excellence in Life Sciences.

For additional insights, the complete report can be downloaded, and more information about ACTO's role-based SuperAgents is accessible at acto.com/superagents. To stay informed on ACTO's latest developments, visit their website or follow the company on LinkedIn.

About Everest Group

Everest Group is a prominent global research firm that supports business leaders in making well-informed decisions. With its PEAK Matrix® assessments, it provides vital analysis and insights that help enterprises navigate the complexities of selecting global service providers and solutions across various markets.

About ACTO

Trusted by a substantial number of pharmaceutical companies and leading biotechs, ACTO is reshaping how therapies are delivered to patients. By combining human insight with empathetic AI, it strives to accelerate product launches and improve customer engagement in the Life Sciences industry, ensuring that every interaction is purposeful and compliant with regulatory standards.